micro-community-banner
Profile Image
  • Saved
Semaglutide in Obesity: Unmet Needs in Men - Diabetes Therapy

Semaglutide in Obesity: Unmet Needs in Men - Diabetes Therapy

Source : https://link.springer.com/article/10.1007/s13300-022-01360-7

Diabetes Therapy (2023) Cite this article FormalPara Key Summary Points Men were understudied in the STEP Phase 3a clinical program. A number of gender-specific differences in efficacy of semaglutide between...



Relevance: A number of gender-specific differences in efficacy of semaglutide between men and women were identified in subgroup analysis overviews of the STEP program.

Profile Image
  • Saved
First-in-Class Oral Semaglutide Overcoming Barriers of Incretinisation in the Indian Context

First-in-Class Oral Semaglutide Overcoming Barriers of Incretinisation in the Indian Context

Source : https://journals.lww.com/indjem/Fulltext/2022/09000/First_in_Class_Oral_Semaglutide__Overcoming.4.aspx

patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers...



Relevance: The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses.

Profile Image
  • Saved
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom - Advances in Therapy

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom - Advances in Therapy

Source : https://link.springer.com/article/10.1007/s12325-022-02423-8

Objectives The objective of the current preliminary study was to present the cost-effectiveness analyses submitted to the National Institute for Health and Care Excellence (NICE) (TA10765) that deemed semaglutide 2.4...



Conclusion: Semaglutide 2.4 mg s.c. injection is a cost-effective therapy compared to D&E alone for patients with obesity and weight-related comorbidities in the UK. Sensitivity and scenario analyses confirm the robustness of the analyses.

Profile Image
  • Saved
Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea - PubMed

Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36604960/

Metformin use in patients with newly diagnosed diabetes was associated with a lower risk of cervical cancer in Korea. Furthermore, a significant association was found between the use of metformin...



Conclusion: Metformin use in patients with newly diagnosed diabetes was associated with a lower risk of cervical cancer in Korea. Furthermore, a significant association was found between the use of metformin and cervical cancer in a dose- and duration-dependent manner and among those over 50 years old.

Profile Image
  • Saved
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany

Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany

Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2007-2061

CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes DOI: 10.1055/a-2007-2061 1   Innere Medizin - Diabetologie und Endokrinologie, Gemeinschaftskrankenhaus Bonn, Bonn, Germany 4   Novo Nordisk Pharma GmbH, Mainz, Germany...



Conclusions: In a real-world population in Germany, patients with type 2 diabetes treated with once-weekly semaglutide experienced clinically significant improvements in glycaemic control and body weight. These results support use of once-weekly semaglutide in routine clinical practice in adult patients with type 2 diabetes in Germany.

Profile Image